BIAXIN XL Drug Patent Profile

When do Biaxin Xl patents expire, and what generic alternatives are available?

Biaxin Xl is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in BIAXIN XL is clarithromycin. There are twenty-one drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the clarithromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Biaxin Xl

A generic version of BIAXIN XL was approved as clarithromycin by ACTAVIS LABS FL INC on June 24^th, 2004.

Summary for BIAXIN XL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	48
Patent Applications:	3,153
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BIAXIN XL
DailyMed Link:	BIAXIN XL at DailyMed

Recent Clinical Trials for BIAXIN XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 2
National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2
National Institute of Neurological Disorders and Stroke (NINDS)	Phase 1/Phase 2

See all BIAXIN XL clinical trials

US Patents and Regulatory Information for BIAXIN XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	BIAXIN XL	clarithromycin	TABLET, EXTENDED RELEASE;ORAL	050775-001	Mar 3, 2000		DISCN	Yes	No

Expired US Patents for BIAXIN XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	BIAXIN XL	clarithromycin	TABLET, EXTENDED RELEASE;ORAL	050775-001	Mar 3, 2000
Abbvie	BIAXIN XL	clarithromycin	TABLET, EXTENDED RELEASE;ORAL	050775-001	Mar 3, 2000
Abbvie	BIAXIN XL	clarithromycin	TABLET, EXTENDED RELEASE;ORAL	050775-001	Mar 3, 2000

International Patents for BIAXIN XL

See the table below for patents covering BIAXIN XL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2009137988	SUSTAINED RELEASE FORMULATION OF ERYTHROMYCIN DERIVATIVE
Slovakia	4862002	EXTENDED RELEASE FORMULATIONS OF ERYTHROMYCIN DERIVATIVES
Canada	2285266	FORMULATIONS A LIBERATION PROLONGEE DE DERIVES D'ERYTHROMYCINE (EXTENDED RELEASE FORMULATIONS OF ERYTHROMYCIN DERIVATIVES)
Colombia	4940403	FORMULACIONES DE LIBERACION PROLONGADA DE DERIVADOS DE ERI- TROMICINA
Czech Republic	294333	Farmaceutická kompozice s prodlouženým uvolňováním clarithromycinu (Pharmaceutical composition for extended release of clarithromycin)

Supplementary Protection Certificates for BIAXIN XL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209

BIAXIN XL Market Analysis and Financial Projection

Last updated: April 26, 2026

Market dynamics and financial trajectory for BIAXIN XL

BIAXIN XL is the extended-release clarithromycin formulation marketed by AbbVie (and historically by Abbott/Abbott Laboratories) for respiratory, skin, and other bacterial infections. The product’s commercial trajectory has shifted from peak oral antibiotic sales toward a mature, shrinking market constrained by (1) patent and exclusivity expiry, (2) generic entry and price erosion, (3) antibiotic stewardship-driven volume pressure, and (4) label narrowing versus newer macrolides and alternative antibiotic classes. The financial profile across major markets is therefore dominated by decline and margin compression rather than sustained growth.

What market does BIAXIN XL compete in?

BIAXIN XL sits in the oral antibiotic market, specifically the macrolide class and, more precisely, extended-release clarithromycin for outpatient bacterial infections. Key competitive dynamics include:

• Therapeutic substitution within macrolides: azithromycin and immediate-release clarithromycin compete on dosing convenience, local resistance patterns, and formulary position.
• Cross-class substitution: penicillins (including beta-lactam/beta-lactamase inhibitor combinations), cephalosporins, and doxycycline often displace macrolides for common outpatient indications based on stewardship guidance and resistance concerns.
• Formulary and payer controls: step therapy, prior authorization, and tier placement increasingly favor preferred agents, especially where generics are available.

Commercial implication: even when BIAXIN XL retains clinical relevance in certain guideline-driven scenarios, incremental share gains are difficult once generic clarithromycin and alternative antibiotics are entrenched.

---

How do patent and exclusivity dynamics shape BIAXIN XL pricing and volume?

The extended-release clarithromycin product line is subject to the standard lifecycle of branded oral generics markets: once formulation or compound protections lapse and generic clarithromycin ER equivalents enter, the branded product typically sees rapid prescription migration.

Market mechanics once exclusivity ends:

• Price compression: generics undercut brand pricing, forcing rebates and contract adjustments.
• Share loss via channel behavior: formularies and pharmacy benefit managers favor generics, especially for antibiotics where clinicians can substitute without complex monitoring.
• Portfolio rationalization: sponsors reduce promotion spend and may reallocate marketing to newer assets or other indications.

Commercial implication: BIAXIN XL’s financial trajectory is expected to follow a predictable branded-antibiotic pattern: peak years under protection, then decline after first meaningful generic penetration, with stabilization only if the brand maintains a distinct clinical or dosing niche.

---

What demand-side forces have pressure effects on BIAXIN XL?

Antibiotic markets have structural demand constraints beyond typical commercial factors:

• Antibiotic stewardship and guideline evolution: pressure to limit macrolide use when benefit is unclear and when resistance risk rises.
• Resistance patterns: increasing macrolide resistance in some respiratory pathogens reduces empirical use in certain geographies.
• Site-of-care shifts: outpatient prescribing practices change with local protocols and payer guidance.
• Diagnostic shifts: faster testing and tighter criteria reduce broad empiric use.

Commercial implication: volume is not purely population-driven; it is governed by appropriateness of prescribing. That limits recovery even after pricing stabilizes.

---

How does generic competition affect BIAXIN XL revenue mechanics?

Generic entry tends to create revenue dynamics with three recurring features:

1. Rapid unit decline: prescriptions shift early to lower-cost equivalents once they are formulary-approved.
2. Lagged net revenue decline: brand revenue may fall faster than unit volumes because of higher rebates needed to retain accounts.
3. Margin squeeze: brand operating contribution compresses as marketing and contracting costs do not fall proportionally to sales.

Commercial implication: the branded sales line for BIAXIN XL historically behaves like a mature product that trades volume for margin during the late-stage lifecycle.

---

What is the likely financial trajectory across the lifecycle?

Given the product is a mature branded antibiotic formulation, its overall financial trajectory is typically:

• Peak period: high outpatient antibiotic demand and protected branding.
• Transition: exclusivity expiration and the beginning of generic pressure.
• Mature decline: continued volume erosion and pricing compression.
• Stabilization (limited): sometimes a residual base remains due to prescribing habits, formulary exceptions, or specific patient or clinician preference, but growth is generally absent.

BIAXIN XL’s market dynamics align with this lifecycle. In practice, sponsors treat such assets as cash contributors late in life and reallocate resources toward pipeline and newer launches.

---

How do payer and channel dynamics determine net revenue vs list price?

For older branded antibiotics, list price is rarely the driver of net sales. Net revenue depends on:

• Rebate intensity: higher rebates to maintain preferred status in PBM contracts.
• Formulary tiers: conversion of brand to a non-preferred tier after generic availability.
• Contract cadence: frequent renegotiation once the payer has multiple low-cost alternatives.
• Pharmacy procurement behavior: retail pharmacy tends to switch to generics at scale when available and when therapeutic substitution is permitted.

Commercial implication: after generic entry, BIAXIN XL’s net revenue typically declines more severely than its observable “market presence,” since contract economics shift quickly.

---

Where do BIAXIN XL economics likely remain resilient?

Even with generic pressure, branded oral antibiotics sometimes retain resilience in:

• Clinician preference for extended-release dosing: some prescribers value adherence advantages tied to once-daily dosing (depending on the clinical scenario and local protocols).
• Specific payer carve-outs: certain plans may preserve brand coverage short-term due to contract timing or channel negotiations.
• Complex patient workflows: where extended-release dosing reduces dosing errors.

These pockets are usually not enough for sustained growth but can slow decline.

---

What are the key performance indicators to track for BIAXIN XL?

For a product with BIAXIN XL’s positioning, the business-critical KPIs tend to be:

• Prescription volume trend (units, not dollars)
• Net sales per prescription (proxy for rebate and price compression)
• Share vs generics within clarithromycin ER equivalents
• Plan formulary status (preferred vs non-preferred)
• Seasonality and respiratory infection correlation (antibiotic seasonality)
• Channel mix (retail vs mail order; mail order may accelerate generic uptake)

Commercial implication: once generics dominate, revenue forecasting should be driven by share and net-per-script, not list price.

---

Key Takeaways

• BIAXIN XL operates in the oral antibiotic macrolide segment, competing against azithromycin, immediate-release clarithromycin, and cross-class alternatives.
• The financial trajectory is structurally biased toward decline once generic clarithromycin ER enters through exclusivity expiry, rebate pressure, and formulary tier shifts.
• Demand is constrained by antibiotic stewardship, diagnostic tightening, and resistance patterns, limiting growth even when pricing stabilizes.
• Net revenue is driven more by contract economics (rebates, tier placement, procurement behavior) than by list price.
• The business case for BIAXIN XL late in life is cash contribution management, with resilience possible only in limited formulary carve-outs or clinician preference for extended-release dosing.

---

FAQs

1) Is BIAXIN XL positioned for growth or decline in its current lifecycle stage?

It is positioned for decline typical of branded oral antibiotics after generic entry, with limited stabilization if niche formulary or prescriber behavior persists.

2) What drives BIAXIN XL revenue changes more: price or volume?

After generic penetration, both change, but net revenue tends to fall faster than unit volume because rebates and contract terms deteriorate.

3) Which competitive products most directly pressure BIAXIN XL?

Immediate-release clarithromycin, azithromycin, and cross-class outpatient antibiotics that displace macrolide use in respiratory infections.

4) How do stewardship policies influence BIAXIN XL demand?

They reduce inappropriate antibiotic prescribing, which directly limits macrolide-based outpatient volumes where clinician discretion and guideline criteria tighten.

5) What is the best way to monitor BIAXIN XL performance during the mature stage?

Track prescriptions, share vs generics, net sales per prescription, and formulary tier status rather than relying on list price trends.

---

References

[1] FDA. “Drugs@FDA: FDA-Approved Drugs.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] IQVIA Institute for Human Data Science. “The use of antibiotics in outpatient care and stewardship trends.” IQVIA Institute (reports and summaries). https://www.iqvia.com/insights/the-iqvia-institute
[3] CDC. “Antibiotic Use in the United States: Progress and Challenges.” Centers for Disease Control and Prevention. https://www.cdc.gov/antibiotic-use/